Galectin Antagonist use in Mild Cases of SARS-CoV-2: Pilot Feasibility Randomised, Open Label, Controlled Trial

Glycovirology

First clinical trial using a galectin antagonist on SARS-CoV-2.  Prolectin-M lowered viral protein levels to undetectable levels in 3 days (Mann Whitney U=0.000, p<0.029) This represents a novel way to block viral entry and replication.  There were no SAE’s and participants were reactive with IgG within 28 days.

Source:

Team

Learn more about the team from BioxyTran

Investors

Learn more about BioxyTran investors and S1 Stocks

Forum

Join the conversation as we discuss Bioxytran's use-cases,
development progress, and more.